title: Reply to the letter by Dr Graham concerning ethical and interpretation issues with vonoprazan-containing H. pylori eradication therapy.
authors.affiliation: Department of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
authors.forename: Kazunari
authors.initials: K
authors.lastname: Murakami
authors.affiliation: Takeda Pharmaceutical Company Ltd., Osaka, Japan.
authors.forename: Yuuichi
authors.initials: Y
authors.lastname: Sakurai
authors.affiliation: Takeda Pharmaceutical Company Ltd., Osaka, Japan.
authors.forename: Madoka
authors.initials: M
authors.lastname: Shiino
authors.affiliation: Takeda Pharmaceutical Company Ltd., Osaka, Japan.
authors.forename: Nobuo
authors.initials: N
authors.lastname: Funao
authors.affiliation: Takeda Pharmaceutical Company Ltd., Osaka, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Nishimura
authors.affiliation: Health Sciences University of Hokkaido, Hokkaido, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
mesh_terms: D000900:Anti-Bacterial Agents; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections; D016480:Helicobacter pylori; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents
keywords: ANTIBIOTIC THERAPY; CLINICAL TRIALS; HELICOBACTER PYLORI INFECTION